Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Experiment Videos

Hypoxic cell radiosensitizers: expectations and progress in drug development.

C N Coleman

    International Journal of Radiation Oncology, Biology, Physics
    |February 1, 1985
    PubMed
    Summary

    Newer hypoxic cell sensitizers, SR 2508 and RO-03-8799, show improved efficacy and reduced toxicity compared to misonidazole (MISO). These advancements may increase local tumor control rates in specific cancer types when used with radiotherapy.

    Related Concept Videos

    You might also read

    Related Articles

    Articles linked to this work by shared authors, journal, and citation graph.

    Sort by
    Same author

    Surveying the Challenges to Improve Linear Accelerator-based Radiation Therapy in Africa: a Unique Collaborative Platform of All 28 African Countries Offering Such Treatment.

    Clinical oncology (Royal College of Radiologists (Great Britain))·2021
    Same author

    Developing Innovative, Robust and Affordable Medical Linear Accelerators for Challenging Environments.

    Clinical oncology (Royal College of Radiologists (Great Britain))·2019
    Same author

    Mobilising Expertise and Resources to Close the Radiotherapy Gap in Cancer Care.

    Clinical oncology (Royal College of Radiologists (Great Britain))·2016
    Same author

    Public health oncology: a framework for progress in low- and middle-income countries.

    Annals of oncology : official journal of the European Society for Medical Oncology·2012
    Same author

    Normal tissue protection for improving radiotherapy: Where are the Gaps?

    Translational cancer research·2012
    Same author

    Advances in cellular and molecular radiation oncology.

    Urologic oncology·2011

    Area of Science:

    • Oncology
    • Radiotherapy
    • Pharmacology

    Background:

    • Misonidazole (MISO) trials initially raised hopes for increased tumor cure rates but showed limited efficacy.
    • The lack of success with MISO discouraged further research into hypoxic cell sensitizers.

    Purpose of the Study:

    • To evaluate the efficacy and toxicity profiles of newer hypoxic cell sensitizers, SR 2508 and RO-03-8799.
    • To clarify the potential clinical benefits of sensitizers in radiotherapy.

    Main Methods:

    • Clinical trials comparing SR 2508 and RO-03-8799 with MISO.
    • Pharmacokinetic analysis to predict and avoid neurotoxicity.
    • Assessment of acute and cumulative toxicity.
    • Evaluation of sensitizer enhancement ratios.

    Related Experiment Videos

    Main Results:

    • SR 2508 is less neurotoxic than MISO, allowing higher doses and potentially avoiding neurotoxicity through pharmacokinetic profiling.
    • RO-03-8799 demonstrates a higher sensitizer enhancement ratio than MISO and has dose-limiting acute toxicity without cumulative effects.
    • The distinct toxicity profiles of SR 2508 and RO-03-8799 suggest potential for simultaneous use with radiation.

    Conclusions:

    • SR 2508 and RO-03-8799 represent significant advancements over MISO in hypoxic cell sensitization.
    • These sensitizers are expected to improve local tumor control, particularly in selected tumor types, rather than overall cure rates in metastatic disease.
    • Future trials will further elucidate the role of hypoxia and sensitizers in clinical radiotherapy.